Form 4: Thermo Fisher CEO Marc Casper Sells Shares Under 10b5-1 Plan

Thermo Fisher Scientific's Chairman and CEO, Marc N. Casper, executed pre-planned stock option exercises and subsequent sales of common stock.

Summary

• Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific Inc., engaged in transactions on September 5, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on April 28, 2025.
• Casper exercised stock options to acquire 400 shares of common stock at an exercise price of $253.99 per share.
• Concurrently, he sold 400 shares of common stock in multiple transactions at prices ranging from $500 to $501.01 per share.
• The net effect on his direct common stock holdings from these specific transactions was zero, as 400 shares were acquired and 400 shares were disposed of.
• Following these transactions, Casper directly beneficially owns 113,762.285 shares of common stock.
• He also indirectly holds shares through various trusts and entities, including 11,300 shares via Alison Casper 2020 Irrevocable Trust, 14,608 shares via Floral Park Associates, Inc., and 5,000 shares via MNC 2020 Irrevocable Trust, disclaiming beneficial ownership except for pecuniary interest.
• He continues to directly own 24,354 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's offset by an option exercise and conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about negative insider sentiment. The CEO still holds a significant number of shares directly and indirectly.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic approach to managing equity rather than a reaction to new, undisclosed information.
• The exercise of options and subsequent sale at significantly higher prices ($500-$501.01 vs. $253.99 exercise price) demonstrates the value creation from previously granted equity compensation.

Negatives

• The sale of 400 shares by the Chairman and CEO, even if pre-planned, represents a reduction in direct common stock holdings.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock transactions, which can influence investor perception of insider confidence and stock valuation.

Key Dates

Recommendation

The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in management's fundamental outlook on the company and does not provide new information that would warrant a change in investment recommendation. The CEO maintains significant direct and indirect holdings.

Keywords

Thermo Fisher Scientific, TMO, Marc N. Casper, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Director, Equity Compensation